Glibenclamide

MECHANISM OF ACTION

Glibenclamide is a second-generation sulfonylurea that lowers blood glucose by stimulating insulin secretion from pancreatic β-cells. It acts by binding to the sulfonylurea receptor (SUR1) component of ATP-sensitive potassium (KATP) channels on β-cell membranes, leading to closure of these channels and membrane depolarization. This depolarization opens voltage-gated calcium channels, allowing an influx of calcium ions, which triggers the exocytosis of insulin-containing granules. The increased insulin release helps reduce blood glucose levels in patients with type 2 diabetes mellitus.

PHARMACOKINETICS

Absorption: Glibenclamide is readily absorbed from the gastrointestinal tract, with micronized formulations providing improved bioavailability.

Distribution: It shows high plasma protein binding, mainly to albumin.

Metabolism: It is extensively metabolized in the liver to weakly active or inactive metabolites, including 4-trans-hydroxy-glibenclamide and 3-cis-hydroxy-glibenclamide.

Elimination: Metabolites are excreted equally through bile (feces) and urine.

PHARMACODYNAMICS

Glibenclamide, also known as glyburide, is a second-generation sulfonylurea that reduces blood glucose levels in type 2 diabetes by enhancing insulin secretion. It works by binding to the sulfonylurea receptor 1 (SUR1) on pancreatic β-cells, leading to closure of ATP-sensitive potassium channels. This causes membrane depolarization, opening of calcium channels, increased intracellular calcium, and ultimately the release of insulin.

DOSAGE AND STRENGTH

Available strengths: Commonly available in 2.5 mg, 5 mg, and 10 mg tablets(strength may vary by country/brand).

Initial dose (type 2 diabetes): Usually started at 2.5 mg to 5 mg once daily, taken with breakfast or the first main meal.

Dose adjustment: Dose may be increased gradually based on blood glucose response, typically in increments of 2.5–5 mg at weekly intervals.

Usual maintenance dose: Commonly 5–10 mg per day, given as a single dose or divided into 2 doses.

Maximum dose: Generally up to 20 mg per day, depending on patient response and tolerance.

Administration note: Should be taken with food to reduce risk of hypoglycemia.

FOOD INTERACTIONS

Glibenclamide (glyburide) is usually taken with the first main meal, typically breakfast, to help reduce the risk of hypoglycemia. Important food-related considerations include alcohol, which can significantly increase the risk of low blood sugar, and large or high-sugar meals, which may contribute to fluctuations in glucose control. There are also limited reports of possible interactions with certain green vegetable drinks (such as aojiru), although this effect is considered weak and not well established.

DRUG INTERACTIONS

Glibenclamide (glyburide) has important drug interactions, particularly with agents that enhance its glucose-lowering effect, such as NSAIDs, alcohol, ciprofloxacin, and miconazole, which may increase the risk of severe hypoglycemia. Drugs that affect its metabolism, such as carbamazepine, can also alter its therapeutic response. As a long-acting sulfonylurea, it requires careful use, especially in elderly patients and those with renal impairment due to a higher risk of prolonged hypoglycemia.

CONTRAINDICATIONS

Glibenclamide is contraindicated in patients with type 1 diabetes mellitus, diabetic ketoacidosis, and in those with severe renal or hepatic impairment, as well as in individuals with known hypersensitivity to sulfonylureas or sulfonamide-related compounds. Its use is generally avoided during pregnancy and breastfeeding. It is also not recommended in situations of severe stress to the body, such as major trauma, serious infections, or during surgical procedures.

SIDE EFFECTS

1. Hypoglycemia: Most common and potentially serious effect (sweating, dizziness, confusion, shakiness)

2. Weight gain: May occur due to increased insulin activity

3. Gastrointestinal effects: Nausea, vomiting, abdominal discomfort, diarrhea

4. Allergic reactions: Skin rash, itching, or rarely hypersensitivity reactions

5. Hematologic effects: Rare cases of anemia, leukopenia, or thrombocytopenia

6. Liver effects: Elevated liver enzymes or rare hepatotoxicity

7. Neurological effects: Headache, dizziness, or fatigue in some patients

OVERDOSE

Glibenclamide overdose can lead to severe and potentially life-threatening prolonged hypoglycemia due to excessive stimulation of insulin release from the pancreas. Symptoms may include dizziness, tremors, sweating, confusion, seizures, and in severe cases, coma. These effects can appear within about 8 hours but may sometimes be delayed. Immediate medical care is required, and treatment often involves intravenous dextrose administration, with additional use of agents such as octreotide in certain cases to control recurrent hypoglycemia.

TOXICITY

Glibenclamide (glyburide) toxicity can lead to severe, prolonged, and potentially life-threatening hypoglycemia due to excessive stimulation of insulin release from the pancreas. This is more likely in cases of overdose or drug accumulation, especially in elderly patients or those with renal impairment. Clinical manifestations may include tremors, sweating, confusion, seizures, and, in severe cases, coma.